AZD1222: Clinical Trials

6 completed. 6 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222 - COVID-19 Vaccine	Phase 2	Completed	Medigen Vaccine Biologics Corp.	804	2022-01-22	2023-03-15
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19	Phase 1 / Phase 2	Completed	R-Pharm	100	2021-09-15	2022-06-03
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) AZD1222, rAd26-S - COVID-19	Phase 1 / Phase 2	Completed	R-Pharm	100	2021-07-13	2022-10-26
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults AZD1222, AZD2816 - COVID-19, SARS-CoV-2	Phase 2 / Phase 3	Completed	AstraZeneca	2843	2021-06-27	2024-09-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention AZD1222, rAd26-S - COVID-19	Phase 2	Completed	R-Pharm	100	2021-03-05	2022-06-03
Study of AZD1222 for the Prevention of COVID-19 in Japan AZD1222, 0.9% (w/v) saline - COVID-19	Phase 1 / Phase 2	Completed	AstraZeneca	256	2020-08-23	2024-03-01